On November 4, 2025, Aspire Biopharma Holdings, Inc. stockholders approved a reverse stock split of 1-for-5 to 1-for-40 and authorized the issuance of over 19.99% of shares upon exercising convertible promissory notes. Votes for the reverse split were 24,965,481 and for share issuance were 19,852,827.